Alkomex GBN Pharma Focuses on Nutraceuticals & Functional Foods in India

New Delhi:  Alkomex GBN Pharma Group looks to tap nutraceutical and functional food segments to drive its growth in the Indian market, according to a company official.

The global pharma company aims for a significant increase in revenue in India by tapping into the nutraceutical and functional food segments, Alkomex GBN Pharma Group Scientific Advisor Dr. Sanjay Agrawal said.

Alkomex is also looking to launch innovative products backed by regional research to expand business in the country.

The company, part of Alkomex GBN, caters to the Indian market with a range of products, including ophthalmic solutions, dermatological products, multivitamins and nutritional supplements, and probiotics.

It has formed partnerships with companies like Danone Group to deliver high-quality healthcare products in the country. It also leverages contract manufacturing to meet the growing demand for these products.

To boost its presence, the company appointed Agrawal, a leading expert in health management and nutraceuticals, as its Scientific Advisor in November last year.

Alkomex GBN in November 2024 announced a global growth and dual-division strategy, focusing on expanding its footprint in Asia and other international markets. Under the strategy, its pharmaceutical division would drive advancements in ophthalmic, dermatological, and healthcare solutions, and the industrial division would provide innovative packaging and industrial materials.

Related Posts

  • Pharma
  • February 17, 2025
  • 74 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 69 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%